JP2016506916A5 - - Google Patents

Download PDF

Info

Publication number
JP2016506916A5
JP2016506916A5 JP2015553788A JP2015553788A JP2016506916A5 JP 2016506916 A5 JP2016506916 A5 JP 2016506916A5 JP 2015553788 A JP2015553788 A JP 2015553788A JP 2015553788 A JP2015553788 A JP 2015553788A JP 2016506916 A5 JP2016506916 A5 JP 2016506916A5
Authority
JP
Japan
Prior art keywords
alkyl
compound according
cycloalkyl
group
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015553788A
Other languages
English (en)
Japanese (ja)
Other versions
JP6347793B2 (ja
JP2016506916A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/011571 external-priority patent/WO2014113413A1/en
Publication of JP2016506916A publication Critical patent/JP2016506916A/ja
Publication of JP2016506916A5 publication Critical patent/JP2016506916A5/ja
Application granted granted Critical
Publication of JP6347793B2 publication Critical patent/JP6347793B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015553788A 2013-01-16 2014-01-15 Ｂｃｌ−２／Ｂｃｌ−ｘＬ阻害薬およびそれを使用した治療方法 Active JP6347793B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361753066P 2013-01-16 2013-01-16
US61/753,066 2013-01-16
PCT/US2014/011571 WO2014113413A1 (en) 2013-01-16 2014-01-15 Bcl-2bcl-xl inhibitors and therapeutic methods using the same

Publications (3)

Publication Number Publication Date
JP2016506916A JP2016506916A (ja) 2016-03-07
JP2016506916A5 true JP2016506916A5 (cg-RX-API-DMAC7.html) 2017-01-26
JP6347793B2 JP6347793B2 (ja) 2018-06-27

Family

ID=51165292

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015553788A Active JP6347793B2 (ja) 2013-01-16 2014-01-15 Ｂｃｌ−２／Ｂｃｌ−ｘＬ阻害薬およびそれを使用した治療方法

Country Status (13)

Country Link
US (2) US9096625B2 (cg-RX-API-DMAC7.html)
EP (2) EP3689886A1 (cg-RX-API-DMAC7.html)
JP (1) JP6347793B2 (cg-RX-API-DMAC7.html)
KR (2) KR102318204B1 (cg-RX-API-DMAC7.html)
CN (3) CN110305162A (cg-RX-API-DMAC7.html)
AU (1) AU2014207716B2 (cg-RX-API-DMAC7.html)
CA (1) CA2897055C (cg-RX-API-DMAC7.html)
ES (1) ES2819232T3 (cg-RX-API-DMAC7.html)
HK (1) HK1219734A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ709635A (cg-RX-API-DMAC7.html)
SG (1) SG11201505525UA (cg-RX-API-DMAC7.html)
WO (1) WO2014113413A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201504902B (cg-RX-API-DMAC7.html)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102318204B1 (ko) * 2013-01-16 2021-10-26 더 리젠츠 오브 더 유니버시티 오브 미시간 Bcl-2bcl-xl 억제제 및 그를 사용하는 치료 방법
RU2716256C2 (ru) 2014-01-28 2020-03-11 Бак Инститьют Фо Ресеч Он Эйджинг Способы и композиции для уничтожения стареющих клеток и для лечения заболеваний и расстройств, ассоциированных со старением
EP3708170A1 (en) 2014-05-05 2020-09-16 BioVentures, LLC Compositions and methods for inhibiting antiapoptotic bcl-2 proteins as anti-aging agents
WO2016014625A1 (en) 2014-07-22 2016-01-28 Board Of Trustees Of The University Of Arkansas Compositions and methods for selectively depleting senescent cells
US20180000816A1 (en) * 2015-02-06 2018-01-04 Unity Biotechnology, Inc. Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions
CA2981753A1 (en) * 2015-02-06 2016-08-11 Unity Biotechnology, Inc. Compounds and uses in treatment of senescence-associated conditions
US11111259B2 (en) 2015-12-18 2021-09-07 Unity Biotechnology, Inc. Acylsulfonamide derivatives for treating senescence-associated diseases and disorders
NZ747404A (en) 2016-03-28 2020-03-27 Presage Biosciences Inc Pharmaceutical combinations for the treatment of cancer
CA3018991A1 (en) * 2016-04-21 2017-10-26 Bioventures, Llc Compounds that induce degradation of anti-apoptotic bcl-2 family proteins and the uses thereof
CN106177955B (zh) * 2016-08-18 2018-03-16 广州威溶特医药科技有限公司 Bcl‑xL抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用
WO2018098534A1 (en) * 2016-12-02 2018-06-07 Garvan Institute Of Medical Research Methods of treating cancer and reagents thereof
EP3441069B1 (en) 2017-08-11 2023-04-05 Unity Biotechnology, Inc. Treatment of diabetic retinopathy using pharmaceutical agents that eliminate senescent cells
WO2019033122A1 (en) * 2017-08-11 2019-02-14 Unity Biotechnology, Inc. TREATMENT OF PULMONARY DISEASES USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS
US20200354336A9 (en) * 2017-08-11 2020-11-12 Unity Biotechnology, Inc. Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells
US10588916B2 (en) 2017-10-31 2020-03-17 Unity Biotechnology, Inc. Technology to inhibit vascular changes that lead to vision loss in the eye
WO2019133988A1 (en) 2017-12-30 2019-07-04 Unity Biotechnology, Inc. Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
KR20200108298A (ko) 2018-01-10 2020-09-17 리커리엄 아이피 홀딩스, 엘엘씨 벤즈아미드 화합물
CA3088253A1 (en) * 2018-01-22 2019-07-25 Bioventures, Llc Bcl-2 proteins degraders for cancer treatment
SI3788042T1 (sl) 2018-04-29 2025-06-30 Beigene Switzerland Gmbh Zaviralci BCL-2
JP7089062B2 (ja) * 2018-04-30 2022-06-21 ユニティ バイオテクノロジー インコーポレイテッド 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Ｂｃｌファミリーアンタゴニストであるホスホリジン
US10738042B2 (en) 2018-04-30 2020-08-11 Unity Biotechnology, Inc. Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
CA3056878C (en) 2018-04-30 2021-03-30 Unity Biotechnology Phospholidines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
US12084423B2 (en) 2018-05-18 2024-09-10 Bioventures, Llc Piperlongumine analogues and uses thereof
US10717722B2 (en) 2018-06-13 2020-07-21 Unity Biotechnology, Inc. Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
MX2020009759A (es) 2018-07-31 2020-10-08 Ascentage Pharma Suzhou Co Ltd Efecto antitumoral sinergico de un inhibidor de bcl-2 combinado con rituximab y/o bendamustina o un inhibidor de bcl-2 combinado con chop.
WO2020024834A1 (en) 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
US11491168B2 (en) 2018-07-31 2022-11-08 Ascentage Pharma (Suzhou) Co., Ltd. Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof
JP7058345B2 (ja) 2018-07-31 2022-04-21 アセンテージ ファーマ（スーチョウ）カンパニー，リミティド Ｂｃｌ－２阻害剤及びＭＤＭ２阻害剤の組合せ製品並びに疾患の予防及び／又治療におけるその使用
CN110772521A (zh) * 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
WO2020024976A1 (en) * 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Combination of bcl-2/bcl-xl inhibitors and chemotherapeutic agent and use thereof
WO2020041405A1 (en) 2018-08-22 2020-02-27 Newave Pharmaceutical Inc. Bcl-2 inhibitors
US11872237B2 (en) * 2018-12-28 2024-01-16 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition and preparation method thereof
US11370807B2 (en) 2019-01-04 2022-06-28 Ascentage Pharma (Suzhou) Co., Ltd. Process for preparing sulfonamide compounds
EP3906235B1 (en) * 2019-01-04 2023-03-15 Ascentage Pharma (Suzhou) Co., Ltd. Method for preparing sulfonamides drugs
TWI770503B (zh) * 2019-05-13 2022-07-11 大陸商蘇州亞盛藥業有限公司 用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物
TW202114692A (zh) * 2019-07-02 2021-04-16 大陸商蘇州亞盛藥業有限公司 一種含有mTOR抑制劑的藥物組合及其應用
AU2020321068A1 (en) * 2019-07-31 2021-03-18 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
WO2021066873A1 (en) 2019-10-03 2021-04-08 Newave Pharmaceutical Inc. Condensed heterocycles as bcl-2 inhibitors
CN112707900B (zh) * 2019-10-24 2022-06-10 上海科技大学 蛋白降解剂及其在疾病治疗中的应用
US12287338B2 (en) * 2019-11-27 2025-04-29 Ascentage Pharma (Suzhou) Co., Ltd. Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway
US20220323465A1 (en) * 2019-12-04 2022-10-13 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical combination and use thereof
CN114786654A (zh) * 2019-12-11 2022-07-22 密执安大学评议会 用于全身递送Bcl-2和Bcl-xL拮抗剂的组合物和方法
CN113350281B (zh) * 2020-03-02 2023-08-15 苏州亚盛药业有限公司 载药聚合物胶束及其制剂和制备方法
WO2021204060A1 (en) * 2020-04-10 2021-10-14 Ascentage Pharma (Suzhou) Co., Ltd. Combinations of bcl-2/bcl-xl inhibitors and related uses
TW202200574A (zh) 2020-04-15 2022-01-01 英屬開曼群島商百濟神州有限公司 Bcl-2抑制劑
WO2021233948A1 (en) 2020-05-19 2021-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat a pathogen lung infection
US20230270816A1 (en) 2020-07-06 2023-08-31 INSERM (Institute National de la Santé et de la Recherche Médicale) Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml)
WO2022012481A1 (en) * 2020-07-13 2022-01-20 Ascentage Pharma (Suzhou) Co., Ltd. Crystalline or Amorphous form of Bcl-2/Bcl-xL inhibitor compound or its salts
CN114053288B (zh) * 2020-07-31 2024-11-19 苏州亚盛药业有限公司 肺部疾病治疗的组合物和方法
EP4244231A4 (en) * 2020-11-10 2024-08-21 Unity Biotechnology, Inc. CRYSTALLINE SOLID MEGLUMIN SALT INHIBITOR OF BCL AND METHOD OF PREPARING AND USING THE SAME
WO2022111647A1 (en) * 2020-11-27 2022-06-02 Ascentage Pharma (Suzhou) Co., Ltd. Formulation combination containing freeze-dried formulation and reconstituted solvent, preparation method and application thereof
US12454674B2 (en) 2020-12-04 2025-10-28 University Of Notre Dame Du Lac Method of encapsulating single cells utilizing an alternating current electrospray
EP4382126A4 (en) * 2021-08-02 2025-07-30 Ascentage Pharma Suzhou Co Ltd PHARMACEUTICAL COMBINATION AND ITS USE
WO2024027706A1 (en) * 2022-08-02 2024-02-08 Beijing Neox Biotech Limited Bcl-xl degrading compounds
CN119923390A (zh) * 2022-09-06 2025-05-02 西藏海思科制药有限公司 一种抑制Bcl-2或Bcl-xL的化合物及其在医药上的应用
WO2024245312A1 (en) * 2023-05-30 2024-12-05 Ascentage Pharma (Suzhou) Co., Ltd. Bcl-2/bcl-xl protein degrader and use thereof
WO2025087879A2 (en) 2023-10-23 2025-05-01 Institut National de la Santé et de la Recherche Médicale Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432304B2 (en) 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
BRPI0514504A (pt) 2004-08-20 2008-06-10 Univ Michigan pequenas moléculas inibidoras de membros da famìlia bcl-2 anti-apoptóticos e os usos das mesmas
CA2606147C (en) 2005-05-12 2011-07-05 Abbott Laboratories Apoptosis promoters
US20070197532A1 (en) 2005-11-18 2007-08-23 Cao Sheldon X Glucokinase activators
CN101534904B (zh) * 2006-09-05 2013-11-06 Abbvie公司 治疗血小板过量的bcl抑制剂
HRP20120577T1 (hr) 2008-07-24 2012-08-31 Nerviano Medical Sciences S.R.L. 3,4-diarilpirazoli kao inhibitori proteinskih kinaza
US20100278921A1 (en) 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
AU2012209295B2 (en) * 2011-01-25 2016-06-30 The Regents Of The University Of Michigan Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same
KR102318204B1 (ko) * 2013-01-16 2021-10-26 더 리젠츠 오브 더 유니버시티 오브 미시간 Bcl-2bcl-xl 억제제 및 그를 사용하는 치료 방법

Similar Documents

Publication Publication Date Title
JP2016506916A5 (cg-RX-API-DMAC7.html)
JP2014507421A5 (cg-RX-API-DMAC7.html)
JP2015532295A5 (cg-RX-API-DMAC7.html)
RU2018138828A (ru) Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами
JP2019529518A5 (cg-RX-API-DMAC7.html)
JP2017528498A5 (cg-RX-API-DMAC7.html)
JP2019510832A5 (cg-RX-API-DMAC7.html)
JP2016513737A5 (cg-RX-API-DMAC7.html)
JP2019516711A5 (cg-RX-API-DMAC7.html)
JP2016536286A5 (cg-RX-API-DMAC7.html)
JP2016509047A5 (cg-RX-API-DMAC7.html)
JP2015534578A5 (cg-RX-API-DMAC7.html)
JP2013507415A5 (cg-RX-API-DMAC7.html)
JP2021502345A (ja) 抗がん剤
JP2019509986A (ja) トリプトライドのグルコース・コンジュゲート、その類縁体及び使用
JP2015508103A5 (cg-RX-API-DMAC7.html)
RU2017112048A (ru) Синергистические комбинации ауристана
JP2020097577A5 (cg-RX-API-DMAC7.html)
JP2017526677A5 (cg-RX-API-DMAC7.html)
JP2016531871A5 (cg-RX-API-DMAC7.html)
CN110248662A (zh) 一种治疗前列腺癌的组合、药物组合物及治疗方法
RU2016122731A (ru) Функционализированные и замещенные индолы в качестве противораковых агентов
JP2015502926A5 (cg-RX-API-DMAC7.html)
JP2015502367A5 (cg-RX-API-DMAC7.html)
JP2017502984A5 (cg-RX-API-DMAC7.html)